Summary: Objectives: The aim of this study was to analyze the impact of deep brain stimulation (DBS) of the posteromedial hypothalamus (pHyp) on seizure frequency in patients with drug‐resistant epilepsy (DRE) associated with intractable aggressive behavior (IAB).Methods: Data were collected retrospectively from nine patients, who received bilateral stereotactic pHyp‐DBS for the treatment of medically intractable aggressive behavior, focusing on five patients who also had DRE. All patients were treated at the Colombian Center and Foundation of Epilepsy and Neurological Diseases—FIRE (Chapter of the International Bureau for Epilepsy), in Cartagena de Indias, Colombia from 2010 to 2014. Each case was evaluated previously by the institutional ethical committee, assessing the impact of aggressive behavior on the patient's family and social life, the humanitarian aspects of preserving the safety and physical integrity of caregivers, and the need to prevent self‐harm. Epilepsy improvement was measured by a monthly seizure reduction percentage, comparing preoperative state and outcome. Additional response to epilepsy was defined by reduction of the antiepileptic drugs (AEDs). Aggressive behavior response was measured using the Overt Aggression Scale (OAS).Results: All the patients with DRE associated with IAB presented a significant decrease of the rate of epileptic seizures after up to 4 years follow‐up, achieving a general 89.6% average seizure reduction from the state before the surgery. Aggressiveness was significantly controlled, with evident improvement in the OAS, enhancing the quality of life of patients and families.Significance: In well‐selected patients, DBS of the pHyp seems to be a safe and effective procedure for treatment of DRE associated with refractory aggressive behavior. Larger and prospective series are needed to define the pHyp as a target for DRE in different contexts.

DBS of the medial forebrain bundle (MFB) has been investigated clinically in major depressive disorder patients with rapid and long-term reduction of symptoms. In the context of chronic bilateral high frequency deep brain stimulation (DBS) of the MFB, the current study looked at the impact of lesioning the ascending dopaminergic pathway at the level of the ventral tegmental area (VTA). Sprague-Dawley female rats were given bilateral injection of 6-OHDA into the VTA (VTA-lx group) or were left unlesioned (control group). Later, all animals received bilateral microelectrode implantation into the MFB followed by chronic continuous stimulation for 3 weeks. Behavioral tests were performed as baseline and following MFB-DBS, along with histological analysis. Pre-stimulation baseline testing of the VTA-lx animals indicated depressive-like phenotype in comparison with controls. Response to MFB-DBS varied according to (i) the degree of dopaminergic depletion: animals with severe mesocorticolimbic dopamine depletion did not, whilst those with mild dopamine loss responded well to stimulation; (ii) environmental conditions and the nature of the behavioral tests, e.g., stressful vs non-stressful situations. Neuromodulation-induced c-fos expression in the prelimbic frontal cortex and nucleus accumbens was also dependent upon integrity of the dopaminergic ascending projections. Our results confirm a potential role for dopamine in symptom relief observed in clinical MFB-DBS. Although mechanisms are not fully understood, the data suggests that the rescue of depressive phenotype in rodents can work via both dopamine-dependent and independent mechanisms. Further investigations concerning the network of depression using neuromodulation platforms in animal models might give insight into genesis and treatment of major depression disorder.